Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMU3IET)

• Drug Name: Thiethylperazine Drug Info
• Synonyms: ETHYLTHIOPERAZINE; Theithylperazine; Thiethylperazinum; Thiethylpipezazine; Thioethylperazine; Tietilperazina; Torecan; Tietilperazina [DCIT]; Thiethylperazinum [INN-Latin]; Torecan (TN); Thiethylperazine (USAN/INN); Thiethylperazine [USAN:INN:BAN]; Norzine (*Dimaleate*); GS-95 (*Dimaleate*)

Indication

Disease Entry	ICD 11	Status	REF
Nausea	MD90	Approved	[1]
Middle East Respiratory Syndrome (MERS)	1D64	Investigative	[2]

• Therapeutic Class: Antiemetics
• Cross-matching ID:
  PubChem CID: 5440
  ChEBI ID: CHEBI:9544
  CAS Number: CAS 1420-55-9
  TTD Drug ID: DMU3IET

Molecule-Related Drug Atlas

Drug(s) Targeting HUMAN clathrin-mediated endocytosis (RME)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Triflupromazine	DMKFQJP	Nausea	MD90	Approved	[2]
Fluphenazine	DMIT8LX	Psychotic disorder	6A20-6A25	Approved	[2]
Promethazine	DM6I5GR	Hyperemesis gravidarum		Approved	[4]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[5]

Drug(s) Targeting Dopamine D2 receptor (D2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[6]
Haloperidol	DM96SE0	Delirium		Approved	[7]
Perphenazine	DMA4MRX	Schizophrenia	6A20	Approved	[8]
Perazine	DM2AOTZ	Psychotic disorder	6A20-6A25	Approved	[9]
Domperidone	DMBDPY0	Gastrointestinal disease	DE2Z	Approved	[10]
Levodopa	DMN3E57	Parkinson disease	8A00.0	Approved	[11]
Quetiapine	DM1N62C	Anorexia nervosa cachexia	6B80	Approved	[12]
Pimozide	DMW83TP	Schizophrenia	6A20	Approved	[13]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[14]
Iloperidone	DM6AUFY	Schizophrenia	6A20	Approved	[15]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Antagonist	[3]
HUMAN clathrin-mediated endocytosis (RME)	TTAIY2U	.	Inhibitor	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7306).
• [2] Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93.
• [3] Antiemetic specificity of dopamine antagonists. Psychopharmacology (Berl). 1982;78(3):210-3.
• [4] Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150.
• [5] Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
• [6] The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
• [7] Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
• [8] CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
• [9] Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
• [10] Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
• [12] Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
• [13] [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
• [14] Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
• [15] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.